Clinical trials of neuroprotection for Parkinson's disease.
Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, The William Beaumont Hospital Research Institute, Royal Oak, Michigan, USA. palewitt@ameritech.net
Peter A
PA
LeWitt
D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003401:Creatine / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008911:Minocycline / Q000627:therapeutic use; D008995:Monoamine Oxidase / Q000502:physiology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010082:Oxepins / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010848:Picolinic Acids / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D019782:Riluzole / Q000627:therapeutic use; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use; D014451:Ubiquinone / Q000627:therapeutic use
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D010082:Oxepins; D010848:Picolinic Acids; C111178:dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine; C031967:rasagiline; D014451:Ubiquinone; D012642:Selegiline; C059303:lazabemide; D019782:Riluzole; D008995:Monoamine Oxidase; D008911:Minocycline; D003401:Creatine